Syndax Pharmaceuticals, Inc. Warrant Down Round Feature Increase Decrease In Equity Amount1
Syndax Pharmaceuticals, Inc. (SNDX) reported Warrant Down Round Feature Increase Decrease In Equity Amount1 of $3.91 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-28.
Discontinued › Shareholders' Equity
us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 · last filed 2023-02-28
- Syndax Pharmaceuticals, Inc. warrant down round feature increase decrease in equity amount1 for fiscal 2020 was $3.91M.
| Period end | Warrant Down Round Feature Increase Decrease In Equity Amount1 12 month |
|---|---|
| 2020-12-31 | $3.91M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |